Vivreon Biosciences LLC

Vivreon Biosciences LLC is a San Diego-based biotechnology company focused on developing novel small molecule therapeutics targeting calcium channel pathways for various medical conditions. Registered in the System for Award Management (SAM) since 2014, the company operates as a for-profit limited liability organization with a strategic emphasis on innovative drug development across multiple therapeutic areas. The company's research and development efforts are primarily centered on developing targeted treatments that modulate calcium release-activated calcium (CRAC) channels to address complex medical conditions.

Through its federal grant awards, Vivreon Biosciences LLC has pursued multiple preclinical therapeutic development projects across diverse medical domains, primarily funded by the National Institutes of Health. The company has received significant grant funding from agencies including the National Institute on Aging, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Heart, Lung, and Blood Institute, and the National Institute on Drug Abuse. Its research projects focus on developing targeted therapeutics for conditions such as Alzheimer's disease, Duchenne muscular dystrophy, ulcerative colitis, opioid use disorder, asthma, primary hyperhidrosis, osteoarthritis, and checkpoint inhibitor-induced enterocolitis. Each grant award involves rigorous preclinical characterization, including toxicity profiling, pharmacokinetic studies, and efficacy testing of small molecule drug candidates designed to modulate specific calcium channel pathways, with the ultimate goal of advancing promising therapeutic candidates toward investigational new drug (IND) applications.